19 results on '"Merola, B"'
Search Results
2. Studio preliminare della secrezione di GH negli ipertiroidismi
- Author
-
Di Lorenzo L. Merola B, Colao A, LUPOLI, GIOVANNI, Lombardi G., BIONDI, BERNADETTE, Di Lorenzo L., Merola B, Colao, A, Biondi, Bernadette, Lupoli, Giovanni, and Lombardi, G.
- Published
- 1994
3. Valutazione della funzione ventricolare sinistra in pazienti con acromegalia: studio radionuclidico
- Author
-
IMBRIACO, MASSIMO, MAUREA, SIMONE, Cuocolo A, Nicolai E, Nappi A, Sullo P, Cardei S, Klain M, Cittadini A, Sabatini D, Colao A, Ferone D, BIONDI, BERNADETTE, Merola B, Fazio S, Squame G, Salvatore M., Imbriaco, Massimo, Cuocolo, A, Nicolai, E, Maurea, Simone, Nappi, A, Sullo, P, Cardei, S, Klain, M, Cittadini, A, Sabatini, D, Colao, A, Ferone, D, Biondi, Bernadette, Merola, B, Fazio, S, Squame, G, and Salvatore, M.
- Published
- 1993
4. Nuovi percorsi di analisi strategica per l’impresa sistema vitale
- Author
-
Piciocchi, Paolo, Saviano, Marialuisa, and Merola, B.
- Subjects
Analisi strategica ,Concorrenti ,Ambiente competitivo - Published
- 2003
5. Efficacia del trattamento cronico con alendronato nell'osteoporosi della malattia di Cushing
- Author
-
C Di Somma, Colao, A, Pivonello, R, Klain, M, Faggiano, A, S Tripodi, F, Merola, B, Salvatore, M, and Lombardi, G
- Subjects
3) 8 patients with active disease treated with ketoconazole alone ,when pituitary surgery was unsuccessful. Study design: Lumbar spine (L1-L4) and femoral neck BMD ,in patients and controls ,serum OC levels were lower (1.1 +/- 0.1 vs 1.5 +/- 0.1 nmol/l ,urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were evaluated at study entry ,P < 0.05) and femoral neck (0.69 +/- 0.3 vs. 0.96 +/- 0.6 g/cm2 ,P < 0.01). In the alendronate-treated groups ,serum OC levels increased ,P < 0.01) ,a significant increase of serum OC levels and a significant decrease of Ntx levels were observed together with a slight increase of BMD values after 12 months. No significant change in either biochemical markers or BMD values was found in patients of group 3. Conclusions: Patients with Cushing's disease have osteoporosis which needs to be rapidly reversed to limit the risk of fracture. The results of the present study show that a 12 month treatment period with alendronate induced an improvement in bone mineral density greater than in untreated patients ,serum osteocalcin (OC) ,2) 11 patients with inactive disease treated with alendronate ,and were repeated after 6 and 12 months in the 39 patients. Results: BMD values were lower in patients with Cushing's disease than in controls at both L1-L4 (0.72 +/- 0.4 vs. 1.01 +/- 0.6 g/cm2 ,Background: Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption. Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption. Objective: We have evaluated the effect of chronic treatment with alendronate on bone mineral density (BMD) in patients with Cushing's disease. Patients: 39 patients with Cushing's disease entered this study. 39 age-, sex- and BMI-matched normals served as controls for baseline evaluation. The 39 patients were divided into four groups: 1) 10 patients with active disease treated with alendronate and ketoconazole ,3) 8 patients with active disease treated with ketoconazole alone, 4) 10 patients with inactive disease received no treatment. Treatment protocol: Alendronate was given for 12 months in a dose of 10 mg orally once daily after fasting at 0800 h in the morning. Ketoconazole was given in a dose of 200-600 mg orally daily, when pituitary surgery was unsuccessful. Study design: Lumbar spine (L1-L4) and femoral neck BMD, serum osteocalcin (OC), urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were evaluated at study entry, in patients and controls, and were repeated after 6 and 12 months in the 39 patients. Results: BMD values were lower in patients with Cushing's disease than in controls at both L1-L4 (0.72 +/- 0.4 vs. 1.01 +/- 0.6 g/cm2, P < 0.05) and femoral neck (0.69 +/- 0.3 vs. 0.96 +/- 0.6 g/cm2, P < 0.05). In the 39 patients with Cushing's disease considered as a whole, serum OC levels were lower (1.1 +/- 0.1 vs 1.5 +/- 0.1 nmol/l, P < 0.01), while Ntx values were higher than in controls (168 +/- 25 vs. 61 +/- 31 nmol BCE/mmol creatinine, P < 0.01). In the alendronate-treated groups, serum OC levels increased, while Ntx levels significantly decreased after 6 and 12 months of treatment without any significant difference between the two groups. BMD values measured at L1-L4 and femoral neck significantly increased after 12 months of therapy. In patients of group 4, a significant increase of serum OC levels and a significant decrease of Ntx levels were observed together with a slight increase of BMD values after 12 months. No significant change in either biochemical markers or BMD values was found in patients of group 3. Conclusions: Patients with Cushing's disease have osteoporosis which needs to be rapidly reversed to limit the risk of fracture. The results of the present study show that a 12 month treatment period with alendronate induced an improvement in bone mineral density greater than in untreated patients ,sex- and BMI-matched normals served as controls for baseline evaluation. The 39 patients were divided into four groups: 1) 10 patients with active disease treated with alendronate and ketoconazole ,P < 0.05). In the 39 patients with Cushing's disease considered as a whole ,while Ntx values were higher than in controls (168 +/- 25 vs. 61 +/- 31 nmol BCE/mmol creatinine ,Background: Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption. Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption. Objective: We have evaluated the effect of chronic treatment with alendronate on bone mineral density (BMD) in patients with Cushing's disease. Patients: 39 patients with Cushing's disease entered this study. 39 age ,while Ntx levels significantly decreased after 6 and 12 months of treatment without any significant difference between the two groups. BMD values measured at L1-L4 and femoral neck significantly increased after 12 months of therapy. In patients of group 4 ,4) 10 patients with inactive disease received no treatment. Treatment protocol: Alendronate was given for 12 months in a dose of 10 mg orally once daily after fasting at 0800 h in the morning. Ketoconazole was given in a dose of 200-600 mg orally daily - Published
- 1998
6. [Usefulness of color echo Doppler with power Doppler in the diagnosis of hypoechoic thyroid nodules: work in progress].
- Author
-
Spiezia S, Colao A, Assanti AP, Cerbone G, Picone GM, Merola B, and Lombardi G
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Retrospective Studies, Thyroid Nodule diagnostic imaging, Ultrasonography, Doppler, Color
- Abstract
The aim of this study was twofold: first, to improve the predictive value of ultrasonography (US) in differentiating benign from malignant thyroid nodules and, second, to investigate whether color Doppler and power Doppler can distinguish different morpho-hemodynamic patterns of hypoechoic thyroid nodules according to their vascularity. Twenty-nine patients with hypoechoic thyroid nodule(s) were entered into this work in progress. Three typical power Doppler patterns were recorded and compared with color Doppler patterns and with cytologic and/or histologic findings. Power Doppler patterns were classified as follows: type A, a perilesional vascular halo; type B, a peri- and intralesional vascular halo, subdivided into: 1) with moderate intralesional vascularization, homogeneous structure and regular vessel caliber and 2) with rich intralesional vascularization, anarchical structure and winding vessel caliber and flow; type C, a perilesional vascular halo with a characteristic peripheral large afferent vessel characterized by winding caliber and flow. Of 29 patients, 21 had type A power Doppler (benign nodular goiter at cytology, in 4 of them with regressive phenomena); seven patients had type B power Doppler patterns-4 had a subtype 1 pattern (3 with nodular hyperplasias and 1 with a papillary adenoma), 3 had a subtype 2 (two had a follicular adenoma and one had a final diagnosis of angioinvasive follicular carcinoma). The patient with undifferentiated carcinoma had a type C power Doppler pattern. In conclusion, according to our early results, PD seems to be more sensitive and reliable than CD in the screening of thyroid nodules, and to yield better vascular information.
- Published
- 1996
7. [Changes of lung volumes and respiratory muscle strength in patients with growth hormone deficiency].
- Author
-
Sofia M, Carratù L, Merola B, Mormile M, Longobardi S, Stanziola A, Molino A, Micco A, and Lombardi G
- Subjects
- Adult, Female, Humans, Male, Muscle Contraction, Respiratory Function Tests, Growth Hormone deficiency, Respiration physiology, Respiratory Muscles physiopathology
- Abstract
The relationship between growth hormone deficiency (GHd) and ventilatory function is not well understood. We studied 7 patients with GHd since childhood who had been adequately treated with replacement therapy until cartilage fusion. Together with 7 well-matched (age and body-type) healthy control subjects, they underwent spirometry including determination of residual volume, and lung diffusing capacity. Also recorded were maximal respiratory muscle pressure during inspiration (PImax) and expiration (PEmax). Patients with GHd showed a significant reduction in total lung capacity and vital capacity while residual volume and lung diffusing capacity remained unchanged. All patients had a significant reduction of both PImax and PEmax. Previously treated adult subjects with GHd present a persistent decrease in lung mobilizing volumes associated with reduced respiratory muscle strength. These alterations may have implications in the management of GHd in adult patients.
- Published
- 1995
8. [GH deficiency in the adult].
- Author
-
Merola B, Longobardi S, Colao A, Rossi E, Esposito V, and Lombardi G
- Subjects
- Adult, Body Composition, Cardiovascular Diseases mortality, Humans, Longevity, Muscle Contraction, Muscles pathology, Myocardial Contraction, Myocardium pathology, Personality, Retrospective Studies, Growth Hormone deficiency
- Published
- 1993
9. [Cardiac effects of GH].
- Author
-
Fazio S, Sabatini D, Cittadini A, Santomauro M, Merola B, Biondi B, Colao A, Lombardi G, and Saccà L
- Subjects
- Acromegaly blood, Acromegaly physiopathology, Adult, Clonidine, Echocardiography, Doppler, Female, Growth Hormone blood, Growth Hormone-Releasing Hormone, Heart Ventricles pathology, Humans, Hypertension complications, Hypertension physiopathology, Insulin-Like Growth Factor I analysis, Male, Middle Aged, Pyridostigmine Bromide, Stroke Volume, Ventricular Function, Left, Acromegaly complications, Cardiomegaly etiology, Growth Hormone deficiency
- Abstract
To investigate cardiac effects of excess and deficiency of growth hormone (GH) we studied twenty acromegalic subjects and eleven adult patients with GH deficiency by means of a non invasive method, the Doppler echocardiography. The results obtained in the group of patients were compared with those of two groups of twenty and eleven normal subjects, respectively, age and sex matched. The age of the acromegalic patients ranged from 20 to 62 years. Nineteen patients were considered to have active acromegaly at the time of the study. Mean duration of disease since treatment was 12 +/- 5 years (range 5 to 24 years). The age of GH deficient adults ranged from 21 to 33 years. All these patients have been treated with extractive GH over nine years and the therapy withdrawal was performed at least three years before entering the study. In the group of acromegalic patients, a subgroup including nine patients with mild to moderate hypertension was considered. All subjects gave informed consent and the study protocol was approved by the Ethical Committee of the Medical School of Naples. Right ventricular free wall thickness resulted significantly increased in acromegalic patients (8 +/- 2 vs 4 +/- 1 mm; p < 0.001). Left ventricular mass index was augmented both in the whole group and in the subgroups of normotensive and hypertensive acromegalics as compared with normals (134 +/- 33 p < 0.001, 115 +/- 20 p < 0.01 and 156 +/- 31 p < 0.001 vs 80 +/- 18 g.m-2). Ejection phase indices were normal in patient group, while impaired left and right ventricular diastolic filling was found.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1993
10. [G-proteins, receptor signal transduction, and growth hormone secretion].
- Author
-
Ventra C, Apicella A, Schettini G, Merola B, and Lombardi G
- Subjects
- Adenoma metabolism, Adenylyl Cyclases physiology, Animals, Arachidonic Acid metabolism, Cyclic AMP physiology, Humans, Hypothalamo-Hypophyseal System physiology, Insulin-Like Growth Factor I physiology, Ion Channels physiology, Neurotransmitter Agents physiology, Phosphatidylinositols physiology, Pituitary Neoplasms metabolism, Protein Kinase C physiology, Somatostatin physiology, GTP-Binding Proteins physiology, Growth Hormone metabolism, Growth Hormone-Releasing Hormone physiology, Receptors, Cell Surface physiology, Signal Transduction physiology
- Published
- 1993
11. [Growth hormone and the heart].
- Author
-
Fazio S, Sabatini D, Cittadini A, Biondi B, Merola B, Colao A, Longobardi S, Lombardi G, and Saccà L
- Subjects
- Acromegaly blood, Acromegaly diagnosis, Acromegaly physiopathology, Adult, Chronic Disease, Diastole, Echocardiography, Doppler, Female, Growth Hormone blood, Growth Hormone-Releasing Hormone, Heart Ventricles diagnostic imaging, Heart Ventricles physiopathology, Humans, Hypertension blood, Hypertension diagnosis, Hypertension physiopathology, Male, Middle Aged, Growth Hormone deficiency, Heart physiopathology
- Abstract
To investigate cardiac effects of excess and deficiency of growth hormone (GH) 20 acromegalic subjects and 11 adult patients with GH deficiency were studied by means of a non invasive method, the Doppler echocardiography. The results obtained in the group of patients were compared with those of 2 groups of 20 and 12 normal subjects, respectively, age and sex matched. The age of the acromegalic patients ranged from 20 to 62 years. Nineteen patients were considered to have active acromegaly at the time of the study. Mean duration of disease since treatment was 12 +/- 5 years (range 5 to 24 years). The age of GH deficient adults ranged from 21 to 33 years. All these patients have been treated with extractive GH over 9 years and the therapy withdrawal was performed at least 3 years before entering the study. In the acromegalic patient group, a subgroup including 9 patients with mild to moderate hypertension was considered. All subjects gave informed consent and the study protocol was approved by the Ethical Committee of the Medical School of Naples. Right ventricular free wall thickness resulted significantly increased in acromegalic patients (8 +/- 2 versus 4 +/- 1 mm; p < 0.001). Left ventricular mass index was augmented both in the whole group and in the subgroup of normotensive acromegalics as compared with normals (134 +/- 33 and 115 +/- 20 versus 80 +/- 18 g.m-2; p < 0.01). Ejection phase indices were normal in patient group, while impaired left and right ventricular diastolic filling was found.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1993
12. [Effectiveness of and tolerability to oral desmopressin in the treatment of central diabetes insipidus].
- Author
-
Merola B, Caruso E, De Chiara G, Rossi E, Longobardi S, Colao A, Brusco G, Lombardi G, and Biraghi M
- Subjects
- Administration, Intranasal, Administration, Oral, Adult, Blood Pressure drug effects, Body Weight drug effects, Deamino Arginine Vasopressin pharmacology, Deamino Arginine Vasopressin therapeutic use, Diabetes Insipidus blood, Diabetes Insipidus urine, Diuresis drug effects, Drug Administration Schedule, Female, Humans, Male, Osmolar Concentration, Specific Gravity drug effects, Deamino Arginine Vasopressin administration & dosage, Diabetes Insipidus drug therapy
- Abstract
Intranasal desmopressin represents the treatment of choice in Central Diabetes Insipidus. Nevertheless, this route of administration bears some practical disadvantage, linked to either difficult delivering technique, or the status of nasal mucose. The antidiuretic effectiveness of oral desmopressin has been recently demonstrated, both in experimental animals and in man. In our study we compared oral vs. intranasal desmopressin efficacy in 13 patients affected by Central Diabetes Insipidus. The results show that the peroral administration of Desmopressin at a mean dose of 500-600 micrograms/die determines an antidiuretic effect comparable to that of intranasal route, without affecting body weight, arterial pressure and chemical analysis. Side effects, generally limited to the first week of treatment, were described (nausea, vomiting, headache, dizziness [corrected], bitter taste, epygastralgia, asthenia, epystassis), inducing 4/13 patients to withdrawal the trial.
- Published
- 1992
13. [Randomized comparative study using carbocalcitonin i.m. vs carbocalcitonin nasal spray vs ipriflavone x os in the treatment of post-menopausal osteoporosis].
- Author
-
Lobianco R, Merola B, Lupoli G, Cocca A, Guarino M, Pia M, Guerriero S, and Lombardi G
- Subjects
- Administration, Intranasal, Administration, Oral, Aged, Calcitonin therapeutic use, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Middle Aged, Osteoporosis, Postmenopausal metabolism, Calcitonin analogs & derivatives, Isoflavones therapeutic use, Osteoporosis, Postmenopausal drug therapy
- Abstract
A comparative study of 90 post-menopausal osteoporotic women, has been carried out. The patients were divided in 3 homogeneous groups. According to 3 different schemes: Group A = 30 patients received carbocalcitonin i.m. 40 UMRC/day/1 month and 40 UMRC/alternating days/2 months followed by 1 month of wash-out for 11 months; Group B = 30 patients received carbolcitonin nasal-spray 80 UMRC/day/1 month and 80 UMRC/alternating day/2 months followed by 1 month of wash-out for 11 months; Group C = 30 patients received ipriflavone x os (600 mg/day/3 months followed by 1 month of wash-out for 3 times). BMC significantly was increased in all Groups after 7 and 11 months. In conclusion, carbocalcitonin and ipriflavone seem to show a similar improving densitometric effect in post-menopausal osteoporosis.
- Published
- 1992
14. [Cerebellar ataxia and hypogonadism. Description of 4 cases].
- Author
-
De Michele G, Filla A, Striano S, Iorio L, Merola B, De Rosa M, Lombardi G, and Campanella G
- Subjects
- Adolescent, Adult, Cerebellar Ataxia blood, Cerebellar Ataxia pathology, Female, Humans, Hypogonadism blood, Hypogonadism pathology, Middle Aged, Sex Characteristics, Cerebellar Ataxia complications, Hypogonadism complications
- Abstract
We describe the association of cerebellar ataxia and hypogonadism in four female patients. Clinical, neurophysiological, neuroradiological and endocrinological features are reported. Post-mortem findings in one case are also described. We show in our patients that, beside the cerebellum, both the supratentorial white matter and the peripheral nerve are involved. We suggest that this association can be considered as a "multiple system atrophy". Furthermore, since hypogonadism is hypergonadotropic in three patients and hypogonadotropic in one, the endocrine pattern appears to be heterogeneous.
- Published
- 1987
15. [Determination of cerebrospinal fluid beta-endorphin during trans-sphenoidal surgery Preliminary note].
- Author
-
Spaziante R, Gargiulo G, Cafiero T, Merola B, Fariello C, Kolodziejmaciejewska H, de Devitiis E, Lombardi G, and Mazzarella B
- Subjects
- Adenoma surgery, Humans, Pituitary Neoplasms surgery, beta-Endorphin, Endorphins cerebrospinal fluid, Sphenoid Sinus surgery
- Published
- 1986
16. [Anesthesiologic problems in transsphenoidal surgery of GH-secreting and ACTH-secreting adenomas].
- Author
-
Cafiero T, Gargiulo G, Spaziante R, Merola B, Carideo P, Cappabianca P, Corcione A, and Mastronardi P
- Subjects
- Adenoma metabolism, Adolescent, Adrenocorticotropic Hormone metabolism, Adult, Aged, Female, Growth Hormone metabolism, Humans, Male, Middle Aged, Pituitary Neoplasms metabolism, Postoperative Complications etiology, Sphenoid Bone, Adenoma surgery, Anesthesia, General adverse effects, Pituitary Neoplasms surgery
- Published
- 1986
17. [Trans-sphenoidal surgery of pituitary adenomas and other forms of pituitary pathology].
- Author
-
De Divitiis E, Spaziante R, Stella L, Cappabianca P, Merola B, and D'Andrea F
- Subjects
- Humans, Sphenoid Bone, Adenoma surgery, Pituitary Diseases surgery, Pituitary Neoplasms surgery
- Published
- 1981
18. [Treatment of early postoperative hypotonic polyuria in pituitary surgery].
- Author
-
Gargiulo G, Spaziante R, Carideo P, Merola B, Cafiero T, Russo A, and Donzelli R
- Subjects
- Humans, Polyuria etiology, Pituitary Gland surgery, Polyuria therapy, Postoperative Complications therapy
- Published
- 1986
19. [Antiemetic effect of the levo isomer of sulpiride (L-sulpiride) in humans].
- Author
-
Schettini G, Mastronardi P, Scanni E, Pinto M, Forgione A, Florio T, Savastano S, Merola B, Lombardi G, and Mazzarella B
- Subjects
- Adolescent, Adult, Anesthesia, General, Antiemetics administration & dosage, Droperidol administration & dosage, Drug Administration Schedule, Female, Humans, Male, Nausea prevention & control, Postoperative Complications prevention & control, Prolactin blood, Random Allocation, Sulpiride administration & dosage, Time Factors, Vomiting prevention & control, Antiemetics therapeutic use, Droperidol therapeutic use, Sulpiride therapeutic use
- Abstract
Vomiting represents one of the most dangerous complications of general anesthesia. L-sulpiride has been able to control this complication very effectively. We studied the effect on vomiting of two doses of L-sulpiride (50/100 mg). Both these doses have been effective in reducing the episodes of vomiting other than in preventing nausea and retching if considered versus controls and also versus droperidol at the doses of 5 mg (50 mg L-sul = 12%, 100 mg = 4%, droperidol = 20%, controls = 28%). L-sulpiride is an antagonist of dopamine on D2 receptors therefore inhibits the action of dopamine increasing the secretion of prolactin. During the surgical distress per se prolactin levels are increased. Together with the increment of catecholamines, high concentration of prolactin can evoke arrhythmias. In view of this possibility we studied the time course of the administration of the two doses of L-sulpiride and of droperidol on prolactin secretion. Both of the drugs increased the plasma levels of prolactin. Droperidol-induced increase in prolactin secretion was significant already at ten minutes after the administration reaching the peak after 20 minutes. L-sulpiride increased prolactin secretion reaching the maximum increase 20 minutes after the administration of 50 mg of the drug, and 30 minutes after the administration of 100 mg doses. The hyperprolactinemizing action of droperidol lasts for at least 8 hours, whereas L-sulpiride action lasts 4 hours.
- Published
- 1989
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.